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Local advanced gastric carcinoma has a very poor prognosis. When a T4 gastric carcinoma has invaded the
surrounding tissues and organs, curative resection is unlikely. We present here a case of a 63-year-old woman with
a T4 unresectable gastric adenocarcinoma. She underwent two 3-week cycles of docetaxel/cisplatin/fluorouracil
chemotherapy, followed by radical gastric resection. Each cycle consisted of 75 mg/m2 docetaxel and 75 mg/m2
cisplatin on day 1, and 200 mg/m2 leucovorin and 500 mg/m2 fluorouracil on days 1 through 5. The patient
exhibited a complete histologic response. Our results indicate that docetaxel/cisplatin/fluorouracil neoadjuvant
chemotherapy is a promising method of treatment for advanced gastric cancer.
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Gastric cancer is one of the most common malignancies
and leading cause of cancer mortality worldwide, with
an estimated 900,000 new cases and more than 700,000
deaths in 2006 alone [1,2]. Radical gastrectomy with ex-
tended lymphadenectomy is now recognized as the only
potentially curative treatment. Patients who present with
stage III or IV disease, however, are not eligible for cura-
tive resection and thus have an especially poor progno-
sis. Moreover, local recurrence or distant metastasis can
develop in a short time even after curative resection [3].
Over the past decade, an increasing number of reports
have shown that neoadjuvant chemotherapy may be use-
ful for patients with advanced T- and N-category lesions,
possibly resulting in downstaging of tumors, improved
rate of primary tumor resection with negative surgical
margins, and early treatment of micrometastatic disease.
We report here a case of a patient with a T4 unresect-
able gastric adenocarcinoma who exhibited a complete
histologic response after docetaxel-based neoadjuvant
chemotherapy.* Correspondence: guominggao203@hotmail.com
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A 63-year-old woman presented to our local hospital
because of epigastric pain. Endoscopic examination re-
vealed a 45 × 52 mm irregular lesion in the lesser curva-
ture of the antrum of the stomach. A biopsy indicated
undifferentiated adenocarcinoma (Figure 1A). Abdom-
inal computed tomography (CT) showed thickening of
the gastric wall. Enlarged metastatic lymph nodes could
not be found. Obliteration of the fat planes between the
gastric tumor and adjacent organs indicated a T4 tumor
[4,5] (Figure 2A). A diagnosis of advanced gastric cancer,
T4NXM0, Stage ΙΙΙA or Ις, was made in accordance with
the current International Union Against Cancer TNM
staging system. Because of the difficulty of performing
a radical operation, we recommended that the patient
undergo chemotherapy.
Neoadjuvant chemotherapy was administered using
docetaxel, cisplatin, fluorouracil, and leucovorin. On
day 1, 75 mg/m2 docetaxel and 75 mg/m2 cisplatin
were administered intravenously. On days 1 through final
day of the cycle 500 mg/m2 fluorouracil and 200 mg/m2
leucovorin were administered. One cycle lasted 3 weeks,
and two cycles were performed. Another CT scan was
performed 2 weeks later. The results showed dramatic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Tumor and histopathological features. (A) Biopsy
indicated undifferentiated adenocarcinoma. (B) Microscopic
examination of the excised specimen showed no remaining gastric
adenocarcinoma cells and coverage of the lesion with regenerative
mucosa. Gland degeneration was seen in the mucosa. Fibrosis and
lymph follicle formation were observed in the gastric wall. (C) No
gastric adenocarcinoma cell remnants were detected even with
immunohistochemistry staining for CK20.
Figure 2 Computed tomography of the gastric wall. (A) Abdominal
computed tomography (CT) scans revealed thickening of the gastric wall.
Obliteration of the fat planes between the gastric tumor and adjacent
organs indicated a T4 tumor. (B) CT scans after two courses of
chemotherapy showed dramatic reduction of the primary lesion and
clarification of the fat planes.
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fat planes between the gastric tumor and adjacent organs
(Figure 2B). Enlarged metastatic lymph nodes and ascites
were not found.
Surgery was performed 4 weeks after neoadjuvant
chemotherapy. No overt peritoneal metastases were
found, and the gastric tumor was not obvious. The surgi-
cal procedure was distal partial gastrectomy with a 5-cmmargin of safety. A D2 lymph node dissection according to
the Japanese Research Society for Gastric Cancer (JRSGC)
guidelines [6] was performed, and 21 lymph nodes were
dissected. The Billroth II method was used for reconstruc-
tion of the alimentary tract.
Macroscopic examination revealed an irregular lesion
extending to proprietary muscle, measuring 10 × 12 mm,
in the lesser curvature of the excised gastric specimen.
Microscopic examination indicated that no gastric adeno-
carcinoma cells remained and the lesion was covered
with regenerative mucosa. Gland degeneration was seen
in the mucosa. Fibrosis and lymph follicle formation were
observed from the submucosa to the subserosa (Figure 1B).
No gastric adenocarcinoma cell remnants were detected
even with immunohistochemistry staining for CK20
(Figure 1C). No lymph node metastasis was found on
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was performed after surgery. Follow-up examination
was conducted every 6 months for a total of 8 years.
The patient remained healthy, with no tumor recur-
rence or metastasis. She was considered to have had a
complete histologic response to treatment with neoad-
juvant chemotherapy.
Discussion
The 5-year survival rate for all gastric carcinoma patients
undergoing surgery is only 20% to 30%. Local recurrence
has been reported to be the main cause of treatment failure
[7]. When T4 gastric carcinoma has invaded the surround-
ing tissues and organs, curative resection is achieved in only
33.3% of cases, although patients who undergo tumor
resection (either curative or noncurative) have a sig-
nificantly better survival rate than those who do not
undergo resection [8].
During the last 20 years, preoperative chemotherapy
has been used in an attempt to decrease the gastric tumor
recurrence rate and increase the survival rate. The two
main goals of neoadjuvant chemotherapy are downstaging
the primary tumor to increase the chances of success-
ful complete resection and destroying occult lymph
nodes and distant metastases. Patients with clinical re-
sponse to chemotherapy have significantly better prog-
noses than those without clinical response, particularly
when complete (R0) resection is performed [9-11].
Several chemotherapy regimens have been developed
for the treatment of advanced gastric cancer. Superior
results have been achieved with epirubicin and cisplatin
plus continuous-infusion fluorouracil (ECF). A phase III
randomized trial showed that, compared with fluorouracil/
doxorubicin/methotrexate, ECF showed a better overall
response rate (ORR) (45% versus 21%), a longer median
time to progression (TTP) (7.4 versus 3.4 months), and
a longer overall survival (OS) (8.9 versus 5.7 months) [12].
Therefore, the investigators proposed ECF as a standard
therapy [12,13]. More recently, several new agents have
emerged, including taxanes, irinotecan, and oxaliplatin.
Docetaxel was the first agent tried in advanced gastric
cancer and showed better activity than the alternatives.
Used as a single agent, docetaxel has been reported to
have response rates between 17% and 29% [14-16].
Combined with other agents, paclitaxel has also shown
promise [17,18]. The combination regimens, including
paclitaxel/5-fluorouracil (5-FU)/cisplatin, resulted in re-
sponse rates as high as 53%, with a median survival of 7
to 14 months [19-23]. The docetaxel/cisplatin/fluorouracil
(DCF) regimen showed efficacy comparable to that of
other regimens of cisplatin or anthracycline combinations.
In the V325 Study Group, Van Cutsem et al. reported that
adding docetaxel to cisplatin and fluorouracil (CF) signifi-
cantly improved TTP, survival, and response rate in gastriccancer patients [22]. In a randomized phase II trial of
the Swiss Group for Clinical Cancer Research, Roth et al.
compared the therapy result of DCF with those of doce-
taxel and cisplatin (DC) and ECF. They reported an ORR
of 25.0% (13 to 41%) for ECF, 18.5% (9 to 34%) for DC,
and 36.6% (23 to 53%) for DCF (n = 119). Median overall
survival times were 8.3, 11.0, and 10.4 months for ECF, DC,
and DCF, respectively [23].
Hematotoxicity was the main adverse effect in docetaxel
trials for advanced gastric cancer. Roth et al. reported a
high incidence of febrile neutropenia associated with the
DCF regimen, which occurred in 41% of patients, com-
pared with only 18% and 21% of patients in the ECF and
DC arms, respectively [23]. After the dose of docetaxel
was reduced, the incidence of febrile neutropenia declined.
According to the literature, 75 mg/m2 docetaxel combined
with CF is well-tolerated, and this dose of docetaxel is most
frequently proposed for treatment of gastric cancer [24-26].
Moreover, a higher incidence of febrile neutropenia did not
translate to a higher mortality rate. This toxicity was ac-
ceptable, and the neutropenia was easily managed with
granulocyte colony-stimulating factor (G-CSF). Interestingly,
the higher incidence of toxicity did not appear to affect
quality of life and clinical benefits, which were signifi-
cantly greater with the DCF regimen, possibly because
of the higher antitumor activity of DCF [22].
The histologic tumor regression grade is an objective
measure of the effects of neoadjuvant chemotherapy.
The overall rate of complete clinical response to DCF for
advanced gastric tumor is 2 to 4.9% [22,23]. The rate of
complete pathologic response, however, has been unknown.
Rapid tumor reduction before curative surgery is an
important indicator of the success of neoadjuvant chemo-
therapy. Roth et al. reported that a DCF regimen resulted
in a shorter median time to treatment response (TTR)
than an ECF regimen (median TTR 1.6 versus 3.0 months)
[23]. The patient with the T4 gastric tumor described here
exhibited a complete pathologic response to DCF chemo-
therapy in 10 weeks. These results indicate that DCF neo-
adjuvant chemotherapy is a promising method of treating
advanced gastric cancer.
Conclusions
In conclusion, we observed a case of locally advanced
gastric carcinoma, which exhibited a complete histologic
response after neoadjuvant chemotherapy; the patient sur-
vived for more than 5 years. According to our experience,
DCF neoadjuvant chemotherapy is a promising method of
treatment for advanced gastric cancer.
Consent
Written informed consent was obtained from the pa-
tient for the publication of this report and any accom-
panying images.
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